Everything You Need To Know About Hybrid/Decentralized Trials

It’s no secret that hybrid and decentralized trials (DCT) are here to stay.

With EY-Parthenon reporting that more than 50% of trials will be decentralized by 2024, many sponsors and CROs are looking to gain the benefits of increased access to traditionally hard-to-reach patients, improved data, higher patient satisfaction, and more

Yet despite adoption, questions, myths, and rumors about what it means to “decentralize a trial,” persist.

Key Learning Objectives:

 Attendees will gain:

• An understanding of hybrid and decentralized clinical trials (DCT)
• Learn the facts and fiction around decentralized trials
• Understand why decentralized trials is not an all or nothing approach

Who Should Attend:

• Pharma Sponsors, Biotechs companies, CROs, University Research heads
  • Clinical operations / development professionals
  • TA lead professionals
  • R&D IT / technology professionals
  • Founder/ President/ CEO/ Executive Directors
  • Chief Medical Officers / Chief Scientific Officers/ Chief Innovation Officers
  • Clinical trial strategy team professionals
  • Heads of data sciences & innovation
  • Digital health professionals